190 related articles for article (PubMed ID: 33033111)
1. In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer.
Rushworth LK; Harle V; Repiscak P; Clark W; Shaw R; Hall H; Bushell M; Leung HY; Patel R
Life Sci Alliance; 2020 Dec; 3(12):. PubMed ID: 33033111
[TBL] [Abstract][Full Text] [Related]
2. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.
Zhen S; Takahashi Y; Narita S; Yang YC; Li X
Oncotarget; 2017 Feb; 8(6):9375-9387. PubMed ID: 28030843
[TBL] [Abstract][Full Text] [Related]
4. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
[TBL] [Abstract][Full Text] [Related]
5. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
6. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
7. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
11. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
13. Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression.
Kabadi AM; Gersbach CA
Methods; 2014 Sep; 69(2):188-97. PubMed ID: 25010559
[TBL] [Abstract][Full Text] [Related]
14. Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
Zhang M; Osisami M; Dai J; Keller JM; Escara-Wilke J; Mizokami A; Keller ET
Mol Cancer Res; 2017 Apr; 15(4):457-466. PubMed ID: 28087740
[TBL] [Abstract][Full Text] [Related]
15. Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells.
Zhu S; Min Z; Qiao X; Chen S; Yang J; Zhang X; Liu X; Ran W; Lv R; Lin Y; Wang J
Aging (Albany NY); 2019 Dec; 11(24):12754-12772. PubMed ID: 31895690
[TBL] [Abstract][Full Text] [Related]
16. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer.
Garrido MF; Martin NJ; Bertrand M; Gaudin C; Commo F; El Kalaany N; Al Nakouzi N; Fazli L; Del Nery E; Camonis J; Perez F; Lerondel S; Le Pape A; Compagno D; Gleave M; Loriot Y; Désaubry L; Vagner S; Fizazi K; Chauchereau A
Clin Cancer Res; 2019 Jan; 25(2):710-723. PubMed ID: 30322877
[TBL] [Abstract][Full Text] [Related]
17. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.
Qu S; Wang K; Xue H; Wang Y; Wu R; Liu C; Gao AC; Gout PW; Collins CC; Wang Y
Mol Oncol; 2014 Mar; 8(2):311-22. PubMed ID: 24388358
[TBL] [Abstract][Full Text] [Related]
18. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
19. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
20. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
